ERBB2 and breast cancer: Although controversy persists as to this finding's true prognostic importance [24], this issue has largely been rendered moot by the recent demonstration of therapeutic efficacy of a monoclonal antibody directed against Her2 in patients with Her2-positive breast cancers [25-27].